Sorrento Therapeutics Inc
NASDAQ:SRNE
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Sorrento Therapeutics Inc
Total Current Liabilities
Sorrento Therapeutics Inc
Total Current Liabilities Peer Comparison
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sorrento Therapeutics Inc
NASDAQ:SRNE
|
Total Current Liabilities
$327.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$41.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
24%
|
CAGR 10-Years
21%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$13B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$19.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
19%
|
CAGR 10-Years
28%
|
See Also
What is Sorrento Therapeutics Inc's Total Current Liabilities?
Total Current Liabilities
327.9m
USD
Based on the financial report for Dec 31, 2022, Sorrento Therapeutics Inc's Total Current Liabilities amounts to 327.9m USD.
What is Sorrento Therapeutics Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 1Y
135%
Over the last year, the Total Current Liabilities growth was 135%.